

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Insulin aspart-szjj (Merilog)

#### Notes:

- Quantity Limits: No
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- ^ insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.

**Initiation (new start) criteria:** Non-formulary **insulin aspart-szjj (Merilog)** will be covered on the prescription drug benefit when the following criteria are met:

- Has a documented allergic reaction to an inactive ingredient in insulin aspart-xjhz (Kirsty) not present in insulin aspart-szjj (Merilog)

#### **-AND-**

**Meets 1 of the following criteria:**

- Diagnosis of type 2 diabetes mellitus with a documented allergy or intolerance\* to regular insulin
- Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus with insulinopenia^

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **insulin aspart-szjj (Merilog)** will be covered on the prescription drug benefit when the following criteria are met:

- Has a documented allergic reaction to an inactive ingredient in insulin aspart-xjhz (Kirsty) not present in insulin aspart-szjj (Merilog)

#### **-AND-**

**Meets 1 of the following criteria:**

- Diagnosis of type 2 diabetes mellitus with a documented allergy or intolerance\* to regular insulin
- Diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus with insulinopenia^

kp.org

cps/awc

Revised 9/11/25

Effective 11/20/25